KYAN Technologies Pte Ltd Press Releases

• Published on April 28, 2022 - 06:20 GMT

  

  KYAN Therapeutics and Aesculape CRO Partner to Offer Drug Development Biopharma Services

  SINGAPORE, April 28, 2022 /⁨EINPresswire.com⁩/ -- KYAN Therapeutics, Inc. (KYAN) and Aesculape CRO (Aesculape) announce plans to offer drug development optimization services for Pharmaceutical and Biotech companies. Studies in recent years estimate that …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on November 23, 2021 - 12:10 GMT

  KYAN Therapeutics Announces Presentation by Collaborators on Personalized Oncology Platform at 63rd ASH Annual Meeting

  Clinical data shows that ex-vivo drug sensitivity platform can help guide clinicians’ treatment of relapsed/refractory cancer patients SINGAPORE, November 23, 2021 /⁨EINPresswire.com⁩/ -- KYAN Therapeutics Inc., a biotech company focused on improved …

  Distribution channels: Companies, Conferences & Trade Fairs ...
• Published on November 11, 2021 - 10:07 GMT

  KYAN Therapeutics Presents Preclinical Data on Novel HDACi Targeting KRAS-mutated Cancers at AACR-KCA Conference

  First in class, selective Class II HDAC inhibitor shows combinatorial effect against KRAS mutations in prostate and pancreatic cancer SINGAPORE, November 11, 2021 /⁨EINPresswire.com⁩/ -- KYAN Therapeutics Inc., a frontier biotech company with a novel drug …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on November 8, 2021 - 12:43 GMT

  

  KYAN Therapeutics announces Hugo Saavedra as CEO

  SINGAPORE, November 8, 2021 /⁨EINPresswire.com⁩/ -- KYAN Therapeutics Inc. (“KYAN”), a frontier biotech company with a novel drug-dose combination optimization platform, Optim.AI, has appointed Hugo Saavedra as Chief Executive Officer effective on January …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...